2021-03-24 |
2021-03-22 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
24 490
-10.0%
22,85
559 601
USD
|
24 490
-10.0%
|
22,85
|
559 601
USD
|
|
2021-03-10 |
2021-03-09 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
19 175
-8.2%
18,12
347 405
USD
|
19 175
-8.2%
|
18,12
|
347 405
USD
|
|
2021-02-11 |
2021-02-09 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
19 175
-8.2%
20,81
399 055
USD
|
19 175
-8.2%
|
20,81
|
399 055
USD
|
|
2021-01-27 |
2021-01-26 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
27 308
-11.3%
18,00
491 544
USD
|
27 308
-11.3%
|
18,00
|
491 544
USD
|
|
2021-01-27 |
2021-01-25 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
30 000
-12.3%
18,01
540 225
USD
|
30 000
-12.3%
|
18,01
|
540 225
USD
|
|
2021-01-21 |
2021-01-20 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
8 567
-3.9%
18,00
154 211
USD
|
8 567
-3.9%
|
18,00
|
154 211
USD
|
|
2021-01-21 |
2021-01-19 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
30 000
-12.3%
18,12
543 552
USD
|
30 000
-12.3%
|
18,12
|
543 552
USD
|
|
2020-07-17 |
2020-07-15 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
378
-0.2%
23,58
8 913
USD
|
378
-0.2%
|
23,58
|
8 913
USD
|
|
2020-07-17 |
2020-07-15 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
9 622
-4.3%
22,94
220 729
USD
|
9 622
-4.3%
|
22,94
|
220 729
USD
|
|
2020-06-25 |
2020-06-23 |
V
Vente
|
MCGUIRE TERRANCE
Administrateur non-exécutif
Actionnaire important
|
4 377
-0.0%
31,54
138 063
USD
|
4 377
-0.0%
|
31,54
|
138 063
USD
|
|
2020-06-25 |
2020-06-23 |
V
Vente
|
Polaris Venture Management Co. VI, L.L.C.
Actionnaire important
|
4 377
-0.0%
31,54
138 063
USD
|
4 377
-0.0%
|
31,54
|
138 063
USD
|
|
2020-06-17 |
2020-06-15 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
3 909
-1.7%
29,90
116 879
USD
|
3 909
-1.7%
|
29,90
|
116 879
USD
|
|
2020-06-17 |
2020-06-15 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
6 091
-2.6%
29,43
179 258
USD
|
6 091
-2.6%
|
29,43
|
179 258
USD
|
|
2020-06-05 |
2020-06-03 |
VP
Vente planifiée
|
Yu Calvin
Vice President, Finance
Dirigeant
|
300
-0.3%
32,02
9 606
USD
|
300
-0.3%
|
32,02
|
9 606
USD
|
|
2020-06-05 |
2020-06-03 |
VP
Vente planifiée
|
Yu Calvin
Vice President, Finance
Dirigeant
|
1 043
-0.9%
31,04
32 375
USD
|
1 043
-0.9%
|
31,04
|
32 375
USD
|
|
2020-05-19 |
2020-05-15 |
VP
Vente planifiée
|
King Robert
Chief Development Officer
Dirigeant
|
3 003
-0.6%
27,78
83 423
USD
|
3 003
-0.6%
|
27,78
|
83 423
USD
|
|
2020-05-19 |
2020-05-15 |
VP
Vente planifiée
|
King Robert
Chief Development Officer
Dirigeant
|
8 632
-1.8%
27,02
233 237
USD
|
8 632
-1.8%
|
27,02
|
233 237
USD
|
|
2020-05-19 |
2020-05-15 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
2 104
-0.9%
27,78
58 449
USD
|
2 104
-0.9%
|
27,78
|
58 449
USD
|
|
2020-05-19 |
2020-05-15 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
5 996
-2.5%
27,00
161 892
USD
|
5 996
-2.5%
|
27,00
|
161 892
USD
|
|
2020-05-19 |
2020-05-15 |
VP
Vente planifiée
|
King Robert
Chief Development Officer
Dirigeant
|
3 365
-0.7%
26,24
88 298
USD
|
3 365
-0.7%
|
26,24
|
88 298
USD
|
|
2020-05-19 |
2020-05-15 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
1 900
-0.8%
26,15
49 685
USD
|
1 900
-0.8%
|
26,15
|
49 685
USD
|
|
2020-04-16 |
2020-04-16 |
V
Vente
|
ORBIMED ADVISORS LLC
Actionnaire important
|
15 086
-0.8%
23,53
354 974
USD
|
15 086
-0.8%
|
23,53
|
354 974
USD
|
|
2020-04-16 |
2020-04-16 |
V
Vente
|
ORBIMED ADVISORS LLC
Actionnaire important
|
47 097
-0.8%
23,53
1 108 192
USD
|
47 097
-0.8%
|
23,53
|
1 108 192
USD
|
|
2020-04-17 |
2020-04-15 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
10 000
-3.9%
22,27
222 700
USD
|
10 000
-3.9%
|
22,27
|
222 700
USD
|
|
2020-04-16 |
2020-04-14 |
V
Vente
|
ORBIMED ADVISORS LLC
Actionnaire important
|
5 636
-0.3%
23,52
132 559
USD
|
5 636
-0.3%
|
23,52
|
132 559
USD
|
|
2020-04-16 |
2020-04-14 |
V
Vente
|
ORBIMED ADVISORS LLC
Actionnaire important
|
17 595
-0.3%
23,52
413 834
USD
|
17 595
-0.3%
|
23,52
|
413 834
USD
|
|
2020-04-09 |
2020-04-09 |
V
Vente
|
ORBIMED ADVISORS LLC
Actionnaire important
|
69 893
-3.5%
23,79
1 662 754
USD
|
69 893
-3.5%
|
23,79
|
1 662 754
USD
|
|
2020-04-09 |
2020-04-09 |
V
Vente
|
ORBIMED ADVISORS LLC
Actionnaire important
|
218 208
-3.5%
23,79
5 191 168
USD
|
218 208
-3.5%
|
23,79
|
5 191 168
USD
|
|
2020-04-09 |
2020-04-08 |
V
Vente
|
ORBIMED ADVISORS LLC
Actionnaire important
|
20 041
-1.0%
23,65
473 970
USD
|
20 041
-1.0%
|
23,65
|
473 970
USD
|
|
2020-04-09 |
2020-04-08 |
V
Vente
|
ORBIMED ADVISORS LLC
Actionnaire important
|
62 573
-1.0%
23,65
1 479 851
USD
|
62 573
-1.0%
|
23,65
|
1 479 851
USD
|
|
2020-04-09 |
2020-04-07 |
V
Vente
|
ORBIMED ADVISORS LLC
Actionnaire important
|
2 224
-0.1%
23,10
51 374
USD
|
2 224
-0.1%
|
23,10
|
51 374
USD
|
|
2020-04-09 |
2020-04-07 |
V
Vente
|
ORBIMED ADVISORS LLC
Actionnaire important
|
6 946
-0.1%
23,10
160 453
USD
|
6 946
-0.1%
|
23,10
|
160 453
USD
|
|
2020-04-02 |
2020-03-31 |
V
Vente
|
ORBIMED ADVISORS LLC
Actionnaire important
|
60 645
-2.9%
24,50
1 485 803
USD
|
60 645
-2.9%
|
24,50
|
1 485 803
USD
|
|
2020-04-02 |
2020-03-31 |
V
Vente
|
ORBIMED ADVISORS LLC
Actionnaire important
|
189 355
-2.9%
24,50
4 639 198
USD
|
189 355
-2.9%
|
24,50
|
4 639 198
USD
|
|
2020-03-25 |
2020-03-25 |
V
Vente
|
ORBIMED ADVISORS LLC
Actionnaire important
|
13 684
-0.7%
24,66
337 447
USD
|
13 684
-0.7%
|
24,66
|
337 447
USD
|
|
2020-03-25 |
2020-03-25 |
V
Vente
|
ORBIMED ADVISORS LLC
Actionnaire important
|
42 727
-0.7%
24,66
1 053 648
USD
|
42 727
-0.7%
|
24,66
|
1 053 648
USD
|
|
2020-03-25 |
2020-03-24 |
V
Vente
|
ORBIMED ADVISORS LLC
Actionnaire important
|
16 409
-0.8%
24,45
401 200
USD
|
16 409
-0.8%
|
24,45
|
401 200
USD
|
|
2020-03-25 |
2020-03-24 |
V
Vente
|
ORBIMED ADVISORS LLC
Actionnaire important
|
51 235
-0.8%
24,45
1 252 696
USD
|
51 235
-0.8%
|
24,45
|
1 252 696
USD
|
|
2020-03-25 |
2020-03-23 |
V
Vente
|
ORBIMED ADVISORS LLC
Actionnaire important
|
3 541
-0.2%
26,05
92 243
USD
|
3 541
-0.2%
|
26,05
|
92 243
USD
|
|
2020-03-25 |
2020-03-23 |
V
Vente
|
ORBIMED ADVISORS LLC
Actionnaire important
|
11 057
-0.2%
26,05
288 035
USD
|
11 057
-0.2%
|
26,05
|
288 035
USD
|
|
2020-03-17 |
2020-03-13 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
176
-0.1%
24,46
4 305
USD
|
176
-0.1%
|
24,46
|
4 305
USD
|
|
2020-03-17 |
2020-03-13 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
5 459
-2.1%
23,49
128 232
USD
|
5 459
-2.1%
|
23,49
|
128 232
USD
|
|
2020-03-17 |
2020-03-13 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
2 884
-1.1%
22,47
64 803
USD
|
2 884
-1.1%
|
22,47
|
64 803
USD
|
|
2020-03-17 |
2020-03-13 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
1 481
-0.6%
21,57
31 945
USD
|
1 481
-0.6%
|
21,57
|
31 945
USD
|
|
2020-03-04 |
2020-03-02 |
V
Vente
|
ORBIMED ADVISORS LLC
Actionnaire important
|
38 808
-100.0%
26,00
1 009 008
USD
|
38 808
-100.0%
|
26,00
|
1 009 008
USD
|
|
2020-03-04 |
2020-03-02 |
V
Vente
|
ORBIMED ADVISORS LLC
Actionnaire important
|
445 086
-17.4%
26,00
11 572 236
USD
|
445 086
-17.4%
|
26,00
|
11 572 236
USD
|
|
2020-03-04 |
2020-03-02 |
V
Vente
|
ORBIMED ADVISORS LLC
Actionnaire important
|
1 390 309
-17.4%
26,00
36 148 034
USD
|
1 390 309
-17.4%
|
26,00
|
36 148 034
USD
|
|
2020-02-18 |
2020-02-14 |
VP
Vente planifiée
|
King Robert
Chief Development Officer
Dirigeant
|
10 332
-2.1%
29,77
307 584
USD
|
10 332
-2.1%
|
29,77
|
307 584
USD
|
|
2020-02-18 |
2020-02-14 |
VP
Vente planifiée
|
King Robert
Chief Development Officer
Dirigeant
|
4 668
-0.9%
29,09
135 792
USD
|
4 668
-0.9%
|
29,09
|
135 792
USD
|
|
2020-02-18 |
2020-02-14 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
7 000
-2.6%
29,74
208 180
USD
|
7 000
-2.6%
|
29,74
|
208 180
USD
|
|
2020-02-18 |
2020-02-14 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
3 000
-1.1%
29,07
87 210
USD
|
3 000
-1.1%
|
29,07
|
87 210
USD
|
|
2020-02-11 |
2020-02-07 |
VP
Vente planifiée
|
Oney Sabah
Chief Business Officer
Dirigeant
|
19 900
-3.4%
35,03
697 097
USD
|
19 900
-3.4%
|
35,03
|
697 097
USD
|
|
2020-02-10 |
2020-02-07 |
VP
Vente planifiée
|
Yu Calvin
Vice President, Finance
Dirigeant
|
24 033
-17.8%
35,02
841 636
USD
|
24 033
-17.8%
|
35,02
|
841 636
USD
|
|
2020-02-10 |
2020-02-06 |
VP
Vente planifiée
|
Yu Calvin
Vice President, Finance
Dirigeant
|
2 621
-2.1%
35,00
91 735
USD
|
2 621
-2.1%
|
35,00
|
91 735
USD
|
|
2020-02-06 |
2020-02-06 |
VP
Vente planifiée
|
Oney Sabah
Chief Business Officer
Dirigeant
|
100
-0.0%
35,00
3 500
USD
|
100
-0.0%
|
35,00
|
3 500
USD
|
|
2020-02-07 |
2020-02-05 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
Dirigeant
|
10 000
-3.5%
32,10
321 000
USD
|
10 000
-3.5%
|
32,10
|
321 000
USD
|
|
2020-02-06 |
2020-02-04 |
VP
Vente planifiée
|
SCHELLER RICHARD H
|
10 000
-50.0%
29,67
296 700
USD
|
10 000
-50.0%
|
29,67
|
296 700
USD
|
|
2020-02-06 |
2020-02-04 |
VP
Vente planifiée
|
Yu Calvin
Vice President, Finance
Dirigeant
|
63 541
-33.6%
30,04
1 908 772
USD
|
63 541
-33.6%
|
30,04
|
1 908 772
USD
|
|
2020-02-06 |
2020-02-04 |
VP
Vente planifiée
|
Oney Sabah
Chief Business Officer
Dirigeant
|
16 667
-2.7%
30,00
500 010
USD
|
16 667
-2.7%
|
30,00
|
500 010
USD
|
|
2020-02-03 |
2020-02-03 |
A
Achat
|
Wehner David M.
|
20 000
+81.2%
25,00
500 000
USD
|
20 000
+81.2%
|
25,00
|
500 000
USD
|
|
2020-02-03 |
2020-01-30 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
|
8 000
-2.8%
28,00
224 000
USD
|
8 000
-2.8%
|
28,00
|
224 000
USD
|
|
2020-01-27 |
2020-01-27 |
VP
Vente planifiée
|
Oney Sabah
Chief Business Officer
|
14 467
-2.4%
25,05
362 398
USD
|
14 467
-2.4%
|
25,05
|
362 398
USD
|
|
2020-01-27 |
2020-01-23 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
|
599
-0.2%
25,22
15 107
USD
|
599
-0.2%
|
25,22
|
15 107
USD
|
|
2020-01-27 |
2020-01-23 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
|
5 401
-1.9%
24,22
130 812
USD
|
5 401
-1.9%
|
24,22
|
130 812
USD
|
|
2020-01-27 |
2020-01-23 |
VP
Vente planifiée
|
Oney Sabah
Chief Business Officer
|
2 200
-0.4%
25,21
55 462
USD
|
2 200
-0.4%
|
25,21
|
55 462
USD
|
|
2020-01-23 |
2020-01-22 |
VP
Vente planifiée
|
King Robert
Chief Development Officer
|
3
-0.0%
22,01
66
USD
|
3
-0.0%
|
22,01
|
66
USD
|
|
2020-01-23 |
2020-01-21 |
VP
Vente planifiée
|
King Robert
Chief Development Officer
|
14 997
-2.9%
22,01
330 084
USD
|
14 997
-2.9%
|
22,01
|
330 084
USD
|
|
2020-01-17 |
2020-01-15 |
VP
Vente planifiée
|
Paul Robert
Chief Medical Officer
|
10 000
-3.5%
18,67
186 700
USD
|
10 000
-3.5%
|
18,67
|
186 700
USD
|
|
2020-01-13 |
2020-01-09 |
V
Vente
|
ORBIMED ADVISORS LLC
Actionnaire important
|
1 392
-3.5%
19,50
27 144
USD
|
1 392
-3.5%
|
19,50
|
27 144
USD
|
|
2020-01-13 |
2020-01-09 |
V
Vente
|
ORBIMED ADVISORS LLC
Actionnaire important
|
91 818
-3.5%
19,50
1 790 451
USD
|
91 818
-3.5%
|
19,50
|
1 790 451
USD
|
|
2020-01-13 |
2020-01-09 |
V
Vente
|
ORBIMED ADVISORS LLC
Actionnaire important
|
286 787
-3.5%
19,50
5 592 347
USD
|
286 787
-3.5%
|
19,50
|
5 592 347
USD
|
|
2019-12-26 |
2019-12-26 |
V
Vente
|
ORBIMED ADVISORS LLC
Actionnaire important
|
1 200
-2.9%
18,60
22 320
USD
|
1 200
-2.9%
|
18,60
|
22 320
USD
|
|
2019-12-26 |
2019-12-26 |
V
Vente
|
ORBIMED ADVISORS LLC
Actionnaire important
|
2 325
-0.1%
18,60
43 245
USD
|
2 325
-0.1%
|
18,60
|
43 245
USD
|
|
2019-12-26 |
2019-12-26 |
V
Vente
|
ORBIMED ADVISORS LLC
Actionnaire important
|
7 275
-0.1%
18,60
135 315
USD
|
7 275
-0.1%
|
18,60
|
135 315
USD
|
|
2019-12-26 |
2019-12-24 |
V
Vente
|
ORBIMED ADVISORS LLC
Actionnaire important
|
8 000
-16.2%
19,59
156 720
USD
|
8 000
-16.2%
|
19,59
|
156 720
USD
|
|